21:08 , May 23, 2019 |  BC Innovations  |  Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest combinations of bispecific small molecules targeting fluorescein and CAIX, PSMA or FOLR1 plus anti-fluorescein CAR T cells could help treat triple-negative breast cancer (TNBC). The bispecific adapter molecules consist...
17:12 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Sanofi drops two clinical assets; reports rebounding Dupixent sales

Sanofi (Euronext:SAN; NYSE:SNY) disclosed in its 2Q18 earnings that it ended development of antibody-drug conjugate (ADC) SAR566658 to treat triple-negative breast cancer (TNBC), as well as a recombinant subunit vaccine to treat tuberculosis. A Sanofi...
22:28 , Jul 31, 2018 |  BC Extra  |  Company News

Sanofi drops two clinical assets; reports rebounding Dupixent sales

Sanofi (Euronext:SAN; NYSE:SNY) disclosed in its 2Q18 earnings that it ended development of antibody-drug conjugate (ADC) SAR566658 to treat triple-negative breast cancer (TNBC), as well as a recombinant subunit vaccine to treat tuberculosis. A Sanofi...
19:50 , Jul 6, 2018 |  BC Extra  |  Preclinical News

New uses for marketed drugs in tough-to-treat indications

Two studies in Science Translational Medicine suggest three generics could be repurposed for difficult to treat indications. A paper from University of Edinburgh researchers showed that endothelial cell-targeted drugs simvastatin and perindopril could help treat...
22:44 , Apr 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy In vitro , mouse and rat studies identified a benzenesulfonamide-based CAII inhibitor that could help treat epilepsy. Chemical synthesis of benzenesulfonamide analogs and in vitro activity assays yielded a compound that inhibited CAII...
20:47 , Nov 10, 2017 |  BC Week In Review  |  Financial News

Telix raises A$50M in Australian IPO

On Nov. 9, Telix Pharmaceuticals Ltd. (ASX:TLX) raised A$50 million ($38.3 million) through the sale of 77 million shares at A$0.65 in an IPO underwritten by Taylor Collison and Wilsons Corporate Finance. The price values...
22:18 , Nov 9, 2017 |  BC Extra  |  Financial News

Telix raises A$50M in Australian IPO

Telix Pharmaceuticals Ltd. (ASX:TLX) raised A$50 million ($38.3 million) through the sale of 77 million shares at A$0.65 in an IPO underwritten by Taylor Collison and Wilsons Corporate Finance. The price values the company at...
19:19 , Jun 2, 2017 |  BC Week In Review  |  Company News

Sanofi, Immunogen amend financials of ADC deals

In exchange for $30 million, ImmunoGen Inc. (NASDAQ:IMGN) and Sanofi (Euronext:SAN; NYSE:SNY) eliminated potential milestone and royalties payments the biotech was eligible to receive under two deals involving five compounds. The candidates are isatuximab, SAR408701...
16:16 , Jan 26, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Crystallographic analyses of H. pylori cah bound to sulfonamides could help guide the design of inhibitors to treat H. pylori infection. Comparative crystallographic studies of bacterial cah and human carbonic anhydrase II...